Piper Sandler initiated coverage on Bristol-Myers
$BMY
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | $55.00 | Neutral | Cantor Fitzgerald |
| 4/22/2025 | Overweight | Piper Sandler | |
| 12/16/2024 | $70.00 | Hold → Buy | Jefferies |
| 12/10/2024 | $63.00 | Neutral | BofA Securities |
| 11/15/2024 | Peer Perform | Wolfe Research | |
| 11/13/2024 | Neutral → Outperform | Daiwa Securities | |
| 11/12/2024 | $73.00 | Market Perform → Outperform | Leerink Partners |
| 10/25/2024 | $75.00 → $55.00 | Buy → Neutral | Citigroup |
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2025, to stockholders of record at the close of business on July 3, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on September 2, 2025, to stockholders of record at the close of business on August 5, 2025. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, de
Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2025 on Thursday, July 31, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol
Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq
Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2025, to stockholders of record at the close of business on July 3, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on September 2, 2025, to stockholders of record at the close of business on August 5, 2025. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, de
95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% maintaining a response at 24 months New data show liso-cel demonstrated high rates of durable responses and a consistent safety profile in a fifth cancer type, the most of any CD19-directed CAR T cell therapy Additional liso-cel data at ICML 2025 further reinforce BMS' commitment to unlocking the full potential of this therapy for patients Bristol Myers Squibb (NYSE:BMY) today announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND
Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS' Leadership in Innovative Cancer Therapies Bristol Myers Squibb (NYSE:BMY) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European Hematology Association (EHA) Annual Congress being held from June 12-15 in Milan, Italy. Presentations feature updated clinical findings on the company's investigational oral CELMoD™ agents mezigdomide and iberdomide in multiple myeloma, and golcadomide in non-Hodgkin lymphoma, as well as the first results evaluating the company's first-in-class, oral BCL6 ligand-directed degrader (LDD) (BMS-986458) in non-Hodgkin lym